Skip to content
Parakho

Torrent Pharmaceuticals Ltd

NSE TORNTPHARMBSE 500420torrentpharma.comInvestor relations

Q2 FY27, unaudited

Revenue
₹4,979.00 Cr
Profit after tax
₹534.00 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ2 FY27vs a year ago6M FY27
Revenue from operations4,979.00+50.79%9,900.00
Other income-10.00+62.96%-22.00
Total income4,969.00+51.73%9,878.00
Employee benefit expense895.00+42.74%1,788.00
Finance costs300.00+525.00%605.00
Depreciation & amortisation609.00+198.53%1,202.00
Total expenses4,222.00+70.86%8,377.00
Profit before tax737.00−6.83%1,470.00
Tax expense203.00+1.50%370.00
Profit after tax534.00−9.64%1,100.00
Total comprehensive income524.00+1.75%1,169.00
Earnings per share
Earnings per share, basic₹14.05₹28.92
Earnings per share, diluted₹14.05₹28.92

Q2 FY27 and 6M FY27 — unaudited, from the company’s filing with NSE. Source

Q2 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

Q2 FY27 results for every company Parakho holds

Earnings call

A transcript for the Q4 FY26 call was filed with the exchange; Parakho has not summarised it yet.

All quarters

Filings

12 shown · 64 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 09 Oct 2026.